TERAPIA CON FAGOS: UN ENFOQUE INNOVADOR PARA TRATAR LAS INFECCIONES POR BACTERIAS RESISTENTES
DOI:
https://doi.org/10.47820/recima21.v6i2.6264Palabras clave:
Bacteriófagos, Terapia con fagos, Resistencia bacteriana, AntibióticosResumen
Entre los problemas a los que se enfrentan las enfermedades infecciosas hoy en día, la resistencia bacteriana a los antibióticos es una amenaza significativa para la salud pública, especialmente en lo que se refiere al tratamiento de las infecciones. Así, en la era de la resistencia a los antibióticos, los bacteriófagos se han convertido en un potencial producto terapéutico contra las infecciones. Los bacteriófagos son virus que infectan bacterias con gran especificidad y que también pueden diseñarse, mediante ingeniería genética, para exterminar cepas resistentes a los antibióticos. En Brasil, al menos un millón de personas al año se ven afectadas por infecciones resistentes, siendo las bacterias más preocupantes Klebsiella pneumoniae, Escherichia coli y Acinetobacter baumanii. La terapia con fagos puede dividirse en dos enfoques principales: personalizado y no personalizado, siendo el primero el que obtiene mejores resultados. Los fagos demostraron ser bien tolerados y seguros, independientemente de la vía utilizada. Sin embargo, los ensayos clínicos aún carecen de una sistematización completa de la metodología, y es crucial promover e invertir en ensayos clínicos bien estructurados para garantizar mejores resultados para los pacientes.
Descargas
Referencias
ABEDON, S. T. Information Phage Therapy Research Should Report. Pharmaceuticals, [S. l.], v. 10, n. 2, abr. 2017. DOI: 10.3390/ph10020043. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490400/. Acesso em: 06 set. 2024. DOI: https://doi.org/10.3390/ph10020043
ADVOCATING for phage therapy. Nature Microbiology, [S. l.], v. 9, p.1397–1398, jun. 2024. DOI: https://doi.org/10.1038/s41564-024-01733-7. Disponível em: https://www.nature.com/articles/s41564-024-01733-7#article-info. Acesso em 20 set. 2024. DOI: https://doi.org/10.1038/s41564-024-01733-7
ALEKSHUN, M. N.; LEVY, S. B. Molecular Mechanisms of Antibacterial Multidrug Resistance. Cell, [S. l.], v. 23, n.128, p.1037-1050, mai. 2007. DOI: 10.1016/j.cell.2007.03.004. Disponível em: https://www.cell.com/action/showPdf?pii=S0092-8674%2807%2900311-X. Acesso em: 2024. DOI: https://doi.org/10.1016/j.cell.2007.03.004
ANTIMICROBIAL RESISTANCE COLLABORATORS. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, [S. l.], v. 399, p. 629-655, fev. 2022. DOI: 10.1016/S0140-6736(21)02724-0. Disponível em: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext. Acesso em: 26 ago. 2024.
ANVISA - AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Confira dados mundiais sobre resistência microbiana. Brasilia: ANVISA, 23 nov. 2021. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/confira-dados-mundiais-sobre-resistencia-microbiana. Acesso em: 17 mar. 2024.
BALASUBRAMANIAN R. et al. Global incidence in hospital-associated infections resistant to antibiotics: An analysis of point prevalence surveys from 99 countries. PLoS Medicine, [S. l.], v. 20, n. 6, jun. 2023. DOI: doi.org/10.1371/journal.pmed.1004178. Disponível em: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004178. Acesso em: 30 ago. 2024. DOI: https://doi.org/10.1371/journal.pmed.1004178
BANCO MUNDIAL. Drug-Resistant Infections: A Threat to Our Economic Future. Washington, DC: World Bank, 2017. Disponível em: https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future. Acesso em: 06 set. 2024.
BRAGG, R. et al. First International Conference, Advances in Experimental Medicine and Biology. Bacteriophages as potential treatment option for antibiotic resistant bactéria, New Delhi, v. 807, p. 97-110, 2014. DOI: 10.1007/978-81-322-1777-0_7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24619620/. Acesso em: 04 mar. 2024. DOI: https://doi.org/10.1007/978-81-322-1777-0_7
BRIVES, C.; POURRAZ, J. Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun, [S. l.], v. 6, n. 100, p. 1-11, 2020. DOI: https://doi.org/10.1057/s41599-020-0478-4. Disponível em: https://www.nature.com/articles/s41599-020-0478-4#citeas. Acesso em: 25 jun. 2024. DOI: https://doi.org/10.1057/s41599-020-0478-4
CDC - CENTERS FOR DISEASE CONTROL AND PREVENTION. Antibiotic resistance threats in the United States. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Disponível em: http://dx.do.i.org/10.15620/cdc:82532. Acesso em: 30 ago. 2024.
CHEVALLEREAU, A. et al. Interactions between bacterial and phage communities in natural environments. Nat. Rev. Microbiol, [S. l.], v. 20, n. 1, p. 49-62, jan. 2022. DOI: 10.1038/s41579-021-00602-y. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34373631/. Acesso em: 18 maio 2024. DOI: https://doi.org/10.1038/s41579-021-00602-y
CLOKIE, M. R. et al. Phages in nature. Bacteriophage, [S. l.], v. 1, n. 1, p. 31-45, jan. 2011. DOI: 10.4161/bact.1.1.14942. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109452/. Acesso em: 01 mai. 2024. DOI: https://doi.org/10.4161/bact.1.1.14942
COHEN, N. Antibiotic resistance: a battle of wits versus natural selection. [S. l.], Harvard University, 2011. Disponível em: https://sitn.hms.harvard.edu/flash/2011/issue103/ Acesso em: 28 maio 2024.
CONLY, J.; JOHNSTON, B. Where are all the new antibiotics? The new antibiotic paradox. Canadian Journal of Infectious Diseases and Medical Microbiology, [s.l.], v. 16, n.3, p. 159-160, mai. 2005. DOI: 10.1155/2005/892058. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095020/. Acesso em: 04 mar. 2024. DOI: https://doi.org/10.1155/2005/892058
DEDRICK, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature Medicine, [S. l.], v. 25, n. 5, p. 730-733, mai. 2019. DOI: 10.1038/s41591-019-0437-z. Disponível em: https://www.nature.com/articles/s41591-019-0437-z. Acesso em: 26 ago. 2024. DOI: https://doi.org/10.1038/s41591-019-0437-z
D'HERELLE, F. Bacteriophage as a Treatment in Acute Medical and Surgical Infections. Bull New York Academy of Medicine. New York, v. 7, n. 5, p. 329-348, mao 1931. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095997/?page=1. Acesso em: 06 ago. 2024.
FEDOROV, E. et al. Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection. Viruses, [S. l.], v, 15, n. 2, p. 499, fev. 2023. DOI: 10.3390/v15020499. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36851713/. Acesso em: 14 out. 2024. DOI: https://doi.org/10.3390/v15020499
FLEMING, A. Chemotherapy: Yesterday, To-Day, and To-Morrow. Cambridge: Cambridge University Press, 1946. p. 39.
FRIEDEN, T. Centers for Disease Control and Prevention. Antibiotic resistance threats. United States: Department of Health and Human Services; 2013. Disponível em: https://www.cdc.gov/antimicrobialresistance/media/pdfs/arthreats2013508.pdf?CDC_AAref_Val=https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Acesso em:17 mar. 2024.
GENCAY, Y. E. et al. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nature Biotechnology, [S. l.], v. 42, p. 265–274, fev. 2024. DOI: https://doi.org/10.1038/s41587-023-01759-y. Disponível em: https://www.nature.com/articles/s41587-023-01759-y. Acesso em: 06 set. 2024. DOI: https://doi.org/10.1038/s41587-023-01759-y
GOODRIDGE, L.; ABEDON, S. T. Bacteriophage biocontrol and bioprocessing: Application of phage therapy to industry. SIM News, [S. l.], v. 53, n. 6, p. 254-262, nov./dez. 2003. Disponível em: https://www.researchgate.net/publication/242411977_Bacteriophage_biocontrol_and_bioprocessing_Application_of_phage_therapy_to_industry. Acesso em: 26 mar. 2024.
HATFULL, G. F.; DEDRICK, R. M; SCHOOLEY, R. T. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annual Review of Medicine, [S. l.], v. 73, n. 27 p.197-211, jan. 2022. DOI: 10.1146/annurev-med-080219-122208. Disponível em: https://www.annualreviews.org/content/journals/10.1146/annurev-med-080219-122208#right-ref-B1. Acesso em: 10 abr. 2024. DOI: https://doi.org/10.1146/annurev-med-080219-122208
HITCHCOCK, N. M. et al. Current Clinical Landscape and Global Potential of Bacteriophage Therapy. Viruses, [S. l.], v. 15, n.4: 1020, abr. 2023. DOI: 10.3390/v15041020. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146840/. Acesso em: 06 set. 2024. DOI: https://doi.org/10.3390/v15041020
JASSIM, S. A.; LIMOGES, R. G. Natural solution to antibiotic resistance: bacteriophages 'The Living Drugs'. World Jounal Microbiology Biotechnology, [S. l.], v. 30, n. 8, p. 2153-2170, ago. 2014. DOI: 10.1007/s11274-014-1655-7. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072922/. Acesso em: 10 abr. 2024. DOI: https://doi.org/10.1007/s11274-014-1655-7
JAULT, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infectious Disease, [S. l.], v. 19, p. 35-45, jan. 2019. DOI: 10.1016/S1473-3099(18)30482-1. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30292481/. Acesso em: 20 set. 2024. DOI: https://doi.org/10.1016/S1473-3099(18)30482-1
KAKASIS, A.; PANITSA, G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. International Journal of Antimicrobial Agents, [S. l.], v. 53, n. 1, p. 16-21, jan. 2019. DOI: 10.1016/j.ijantimicag.2018.09.004. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0924857918302632?via%3Dihub. Acesso em: 10 abr. 2024. DOI: https://doi.org/10.1016/j.ijantimicag.2018.09.004
LEITNER, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infectious Disease, [S. l.], v. 21, n. 3, p. 427-436, mar. 2021. DOI: 10.1016/S1473-3099(20)30330-3. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32949500/. Acesso em: 18 set. 2024. DOI: https://doi.org/10.1016/S1473-3099(20)30330-3
LUONG, T.; SALABARRIA, A.C.; ROACH, D.R. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? Clinical Theraphy, [S. l.], v. 42, n. 9, p. 1659-1680, set. 2020. DOI: 10.1016/j.clinthera.2020.07.014. Disponível em: https://www.clinicaltherapeutics.com/article/S0149-2918(20)30348-9/fulltext. Acesso em: 11 maio 2024. DOI: https://doi.org/10.1016/j.clinthera.2020.07.014
MALIK, D. J. et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Advances in Colloid and Interface Science, [S. l.], v.249, p. 100-133, nov. 2017. DOI: 10.1016/j.cis.2017.05.014. Disponível em: https://www.sciencedirect.com/science/article/pii/S000186861630392X?via%3Dihub. Acesso em: 16 dez. 2024. DOI: https://doi.org/10.1016/j.cis.2017.05.014
MARCUK, L. M. et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bulletin of the World Health Organization, [S. l.], v. 45, n. 1, p. 77-83, 1971. Disponível em: https://pubmed.ncbi.nlm.nih.gov/4946956/. Acesso em: 14 out. 2024.
MUTEEB, et al. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Pharmaceuticals (Basel), [S. l.], v. 16, n. 11, p. 1615, nov. 2023. DOI: 10.3390/ph16111615. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675245/ Acesso em: 28 ago. 2024. DOI: https://doi.org/10.3390/ph16111615
OMS - ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global antimicrobial resistance and use surveillance systems | Country Profiles. [S. l.]: Global Health Observatory, 2019. Disponível em: https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles. Acesso em: 18 set. 2024
OMS - ORGANIZAÇÃO MUNDIAL DE SAÚDE. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization, 2014. Disponível em: https://www.who.int/publications/i/item/9789241564748. Acesso em: 04 nov. 2024.
OMS - ORGANIZAÇÃO MUNDIAL DE SAÚDE. Bacterial Priority Pathogens List, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. Disponível em: https://www.who.int/publications/i/item/9789240093461. Acesso em: 29 ago. 2024.
OMS - ORGANIZAÇÃO MUNDIAL DE SAÚDE. Incentivising the development of new antibacterial treatments 2023. [S. l.]: Global AMR R&D Hub & WHO, 2023. Disponível em: https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-gcp-irc/incentivising-development-of-new-antibacterial-treatments-2023---progress-report.pdf?sfvrsn=72e4f738_3. Acesso em: 11 mai. 2024.
PARDO-FREIRE, M.; DOMINGO-CALAP, P. Phages and Nanotechnology: New Insights against Multidrug-Resistant Bacteria. Biodesingn Research, [S. l.], v.5, p. 1-13, jan, 2023. DOI: 10.34133/bdr.0004. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10521656/. Acesso em: 16 dez. 2024. DOI: https://doi.org/10.34133/bdr.0004
PELFRENE, E. et al. Bacteriophage therapy: a regulatory perspective. Journal of Antimicrobial Chemotherapy, [S. l.], v. 71, n. 8, p. 2071-2074, ago.2016. DOI: https://doi.org/10.1093/jac/dkw083. Disponível em: https://academic.oup.com/jac/article/71/8/2071/2237822?login=false. Acesso em: 20 set. 2024. DOI: https://doi.org/10.1093/jac/dkw083
PIRNAY, J. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nature Microbiology, [S. l.], v. 9, p. 1434-1453, jun. 2024. DOi: https://doi.org/10.1038/s41564-024-01705-x. Disponível em: https://www.nature.com/articles/s41564-024-01705-x. Acesso em: 20 set. 2024.
PIRNAY, J. Phage Therapy in the Year 2035. Frontiers Microbiology, [S. l.], v. 11, n. 1171, jun. 2020. DOI: 10.3389/fmicb.2020.01171. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284012/. Acesso em: 14 out. 2024. DOI: https://doi.org/10.3389/fmicb.2020.01171
RODRIGUEZ, J. M. et al. Case Report: successful use of phage therapy in refractory MRSA chronic rhinosinusitis. International Journal of Infectious Diseases, [S. l.], v. 121, p. 14-16, ago. 2022. DOI: 10.1016/j.ijid.2022.04.049. Disponível em: https://www.ijidonline.com/article/S1201-9712(22)00247-8/fulltext. Acesso em: 18 set. 2024. DOI: https://doi.org/10.1016/j.ijid.2022.04.049
RUBALSKII, E. et al. Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics (Basel), [S. l.], v.9, n. 5:232, mai. 2020. DOI: 10.3390/antibiotics9050232. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277081/. Acesso em: 28 ago. 2024. DOI: https://doi.org/10.3390/antibiotics9050232
SABINO, Y. N. V. et al. Characterization of antibiotic resistance genes in the species of the rumen microbiota. Nature Comumunications, [S. l.], v. 10, n. 5252, p. 1-11, nov. 2019. DOI: 10.1038/s41467-019-13118-0. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868206/. Acesso em: 01 mai. 2024. DOI: https://doi.org/10.1038/s41467-019-13118-0
SARKER, S. A. et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. eBioMedicine, [S. l.], v. 4, p. 124-137, feb. 2016. DOI: 10.1016/j.ebiom.2015.12.023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26981577/. Acesso em: 20 set. 2024. DOI: https://doi.org/10.1016/j.ebiom.2015.12.023
SARKER, S. A. et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology, [S. l.], v 434, n. 2, p. 222-232, jan. 2012. DOI: 10.1016/j.virol.2012.09.002. Disponível em: https://www.sciencedirect.com/science/article/pii/S0042682212004436?pes=vor. Acesso em: 20 set. 2024. DOI: https://doi.org/10.1016/j.virol.2012.09.002
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 32, n. 3, p. 317-335, 1984. Disponível em: https://pubmed.ncbi.nlm.nih.gov/6395825/. Acesso em: 14 out. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 33, n. 2, p. 219-240, 1985. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2935115/. Acesso em: 14 out. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 33, n. 2, p. 219-240, 1985. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2935116/. Acesso em: 14 out. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 33, n. 2, p. 261-273, 1985. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2935117/. Acesso em: 14 out. 2024.
SMOLINSKI, M. S.; HAMBURG, M. A.; LEDERBERG, J. Microbial Threats to Health: Emergence, Detection, and Response. Washington: The National Academies Press, 2003. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK221483/#ddd00042. Acesso em: 28 fev. 2024.
STRATHDEE, S. A. et al. Phage therapy: From biological mechanisms to future directions. Cell, [S. l.], v. 186, n. 1, p. 17-31, jan. 2023. DOI: 10.1016/j.cell.2022.11.017. Disponível em: https://www.cell.com/cell/fulltext/S00928674(22)014611?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867422014611%3Fshowall%3Dtrue. Acesso em: 21 abr. 2024.
SUH, G. A. et al. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrobial Agents and Chemotheraphy, [S. l.], v. 66, n. 3, mar. 2022. DOI: 10.1128/AAC.02071-21. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923208/. Acesso em: 20 set. 2024. DOI: https://doi.org/10.1128/aac.02071-21
SUTCLIFFE, S. G; REYES, A.; MAURICE, C. F. Bacteriophages playing nice: Lysogenic bacteriophage replication stable in the human gut microbiota. IScience, [S. l.], v. 26, n. 2, p. 1-14, fev. 2023. DOI: https://doi.org/10.1016/j.isci.2023.106007. Disponível em: https://www.cell.com/iscience/fulltext/S2589-0042(23)00084-6#%20. Acesso em: 11 maio 2024. DOI: https://doi.org/10.1016/j.isci.2023.106007
VIERTEL, T. M.; RITTER, K., HORZ, H. Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. Journal of Antimicrobial Chemotherapy, [S. l.], v. 69, p. 2326-2336, mai. 2014. DOI: 10.1093/jac/dku173. Disponível em: https://academic.oup.com/jac/article/69/9/2326/2911275?login=false. Acesso em: 18 maio 2024. DOI: https://doi.org/10.1093/jac/dku173
WRIGHT, A. et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical Otolaryngology, [S. l.], v. 34, n. 4 p. 349-457, ago. 2009. DOI: 10.1111/j.1749-4486.2009.01973.x. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/j.1749-4486.2009.01973.x. Acesso em: 06 set. 2024. DOI: https://doi.org/10.1111/j.1749-4486.2009.01973.x
Descargas
Publicado
Número
Sección
Categorías
Licencia
Derechos de autor 2025 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.